# Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

> **NCT06243185** · PHASE2 · UNKNOWN · sponsor: **Fengzhi Feng** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Dalpiciclib plus letrozole

## Key facts

- **NCT ID:** NCT06243185
- **Lead sponsor:** Fengzhi Feng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-17
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06243185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06243185, "Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06243185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*